Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

In our October International Strategy, we provide a synopsis on current market conditions around the globe, and explore the following themes in further detail:<ul>
<li>Supporting our cautious outlook, cyclical and growth Sectors are breaking down on the international front - namely Technology and Consumer Discretionary.  </li>
<li>Overweight Norway.</li>
<li>Price support holding in Japan as RS improves. </li>
<li>Health Care remains attractive, especially defensive pharma Groups within Japan and Europe.</li>
</ul>

In our October International Strategy, we provide a synopsis on current market conditions around the globe, and explore the following themes in further detail:
Supporting our cautious outlook, cyclical and growth Sectors are breaking down on the international front - namely Technology and Consumer Discretionary.  
Overweight Norway.
Price support holding in Japan as RS improves. 
Health Care remains attractive, especially defensive pharma Groups within Japan and Europe.


Global Equity Strategy: Market Deterioration Continues; Cyclical & Growth Sectors Breaking Down

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

Recent developments in <a href="https://www.smartkarma.com/entities/22932" target="_blank" data-smartkarma-citation="entities:22932:1">Samsung Biologics Co., (207940 KS)</a>'s business have been mixed with a negative skew. First, partner <a href="https://www.smartkarma.com/entities/26820" target="_blank" data-smartkarma-citation="entities:26820:1">Merck &amp; Co Inc (MRK UN)</a> terminated a product development project, reducing long-term revenue and earnings prospects. Second, recent biosimilar product launches face increased competition relative to prior launches. Third, the CMO business' capacity is expanding dramatically while backlogs have been stagnant. Fourth, accounting controversies are returning to the fore. The company's US$27 billion market cap remains a function of earnings prospects in 4-5 years, which we think are likely to disappoint.

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck &amp; Co Inc (MRK UN) terminated a product development project, reducing long-term revenue and earnings prospects. Second, recent biosimilar product launches face increased competition relative to prior launches. Third, the CMO business' capacity is expanding dramatically while backlogs have been stagnant. Fourth, accounting controversies are returning to the fore. The company's US$27 billion market cap remains a function of earnings prospects in 4-5 years, which we think are likely to disappoint.

Today's report puts a spotlight on the Health Care Sector, which is assuming a global leadership role vs. other Sectors. We also focus on the Communications Sector as we are seeing steady relative strength ranking (RSR) improvements over the last couple of months. At the Group level, we highlight select smid-cap Casinos &amp; Gaming stocks. Finally, India’s S&amp;P BSE SENSEX is breaking out to new all-time highs as RS bullishly inflects, we highlight actionable stocks.

Today's report puts a spotlight on the Health Care Sector, which is assuming a global leadership role vs. other Sectors. We also focus on the Communications Sector as we are seeing steady relative strength ranking (RSR) improvements over the last couple of months. At the Group level, we highlight select smid-cap Casinos &amp; Gaming stocks. Finally, India’s S&amp;P BSE SENSEX is breaking out to new all-time highs as RS bullishly inflects, we highlight actionable stocks.

Global Strategy: Health Care Outperforming - Overweight; India Breaking Out -Add Exposure

Healthcare Specialist

Winnie Wong

The Securities and Exchange Commission (SEC) believes that insider trading occurred around <a href="https://www.smartkarma.com/entities/4564" target="_blank" data-smartkarma-citation="entities:4564:1">Sanofi (SAN FP)</a> 's $11.6 billion deal for <a href="https://www.smartkarma.com/entities/26434" target="_blank" data-smartkarma-citation="entities:26434:1">Bioverativ Inc (BIVV US)</a> .  Last Friday, <a href="https://www.sec.gov/litigation/litreleases/2018/lr24035.htm" target="_blank">SEC filed a lawsuit</a> in the US District Court for the Southern District of New York against “unknown traders” who made “a series of suspicious transactions” surrounding the announcement of a definitive agreement under which Sanofi will acquire Bioverativ".The regulator believes that the traders allegedly used foreign broker…

The Securities and Exchange Commission (SEC) believes that insider trading occurred around Sanofi (SAN FP) 's $11.6 billion deal for Bioverativ Inc (BIVV US) .  Last Friday, SEC filed a lawsuit in the US District Court for the Southern District of New York against “unknown traders” who made “a series of suspicious transactions” surrounding the announcement of a definitive agreement under which Sanofi will acquire Bioverativ".The regulator believes that the traders allegedly used foreign broker…

Insider Trading Alleged as Sanofi Continues Its Shopping Spree

Today, <a href="https://www.smartkarma.com/entities/4564" target="_blank" data-smartkarma-citation="entities:4564:1">Sanofi (SAN FP)</a> announced that it is acquiring <a href="https://www.smartkarma.com/entities/26434" target="_blank" data-smartkarma-citation="entities:26434:1">Bioverativ Inc (BIVV US)</a> for $11.6 billion (a 64% premium).  Management hosted a conference call and webcast on the acquisition today at 2 pm CET / 8 am ET / 23 January 12 am AEST (not so great if you live in Australia like me!).<h2>Transaction Highlights    </h2><ul>
<li>Bioverativ shareholders will receive $105 per share in cash</li>
<li>The transaction is valued at approximately $11.6 billion on a fully diluted basis</li>
<li>FY2018 EPS accretive and up to 5% accretive in…</li>
</ul>

Today, Sanofi (SAN FP) announced that it is acquiring Bioverativ Inc (BIVV US) for $11.6 billion (a 64% premium).  Management hosted a conference call and webcast on the acquisition today at 2 pm CET / 8 am ET / 23 January 12 am AEST (not so great if you live in Australia like me!).Transaction Highlights    
Bioverativ shareholders will receive $105 per share in cash
The transaction is valued at approximately $11.6 billion on a fully diluted basis
FY2018 EPS accretive and up to 5% accretive in…


Sanofi: Stop the Bleeding with Bioverativ

United States

Sanofi is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines.  The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sanofi ADR (SNY US)

Global Equity Strategy: Market Deterioration Continues; Cyclical & Growth Sectors Breaking Down

In our October International Strategy, we provide a synopsis on current market conditions around the globe, and explore the following themes in...

Vermilion Research

Samsung BioLogics Update

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...

Kemp Dolliver, CFA

Global Strategy: Health Care Outperforming - Overweight; India Breaking Out -Add Exposure

Today's report puts a spotlight on the Health Care Sector, which is assuming a global leadership role vs. other Sectors. We also focus on...

Vermilion Research

Insider Trading Alleged as Sanofi Continues Its Shopping Spree

The Securities and Exchange Commission (SEC) believes that insider trading occurred around Sanofi (SAN FP) 's $11.6 billion deal for Bioverativ Inc...

Winnie Wong

Sanofi: Stop the Bleeding with Bioverativ

Today, Sanofi (SAN FP) announced that it is acquiring Bioverativ Inc (BIVV US) for $11.6 billion (a 64% premium). Management hosted a conference...

Winnie Wong

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)